- Clinically relevant core genes for hematologic malignancies in clinical NGS panel testing
-
Song JS
- KMID: 2550201
- Blood Res.
- 2023 Dec;58(4):224-228.
- doi: 10.5045/br.2023.2023196
-
- CITED
-
- Close
- SHARE
-
- Close
- Clinico-pathological features and treatment outcomes of high-grade B cell lymphoma—a tertiary cancer center experience
-
Mukherjee A, Rainchwar S, Singh A, Halder R, Patra PC, Ahmed R, Bhurani D, Agrawal N
- KMID: 2550207
- Blood Res.
- 2023 Dec;58(4):240-242.
- doi: 10.5045/br.2023.2023169
-
- CITED
-
- Close
- SHARE
-
- Close
- Incidental abdominal computed tomography findings in patients newly diagnosed with Philadelphia-negative myeloproliferative neoplasm
-
Song IC, Koh JS, Kang S, Lee MW, Shin KS, Jo DY
- KMID: 2550200
- Blood Res.
- 2023 Dec;58(4):221-224.
- doi: 10.5045/br.2023.2023049
-
- CITED
-
- Close
- SHARE
-
- Close
- Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma
-
Aydin MS, Cengiz E, Can F, Dagdas S, Dilek I, Ozet G
- KMID: 2550204
- Blood Res.
- 2023 Dec;58(4):234-237.
- doi: 10.5045/br.2023.2023182
-
- CITED
-
- Close
- SHARE
-
- Close
- T-cell large granular lymphocytic leukemia with low-grade bone marrow involvement complicated by acquired pure red cell aplasia
-
Strasser B, Heibl S, Thaler J, Haushofer A
- KMID: 2550203
- Blood Res.
- 2023 Dec;58(4):231-234.
- doi: 10.5045/br.2023.2023141
-
- CITED
-
- Close
- SHARE
-
- Close
- Flower-shaped lymphocytes in CD5+ diffuse large B-cell lymphomaÊs leukemic phase
-
Galiacho VR, Gallardo PZ, Dueñas LZ, Fuentes BDDL, García-Ruiz JC
- KMID: 2550192
- Blood Res.
- 2023 Dec;58(4):165-165.
- doi: 10.5045/br.2023.2023178
-
- CITED
-
- Close
- SHARE
-
- Close
- Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement
-
Jang SY, Byun JM, Yoon SS, Paeng JC, Lee SP, Koh Y
- KMID: 2550208
- Blood Res.
- 2023 Dec;58(4):242-245.
- doi: 10.5045/br.2023.2023194
-
- CITED
-
- Close
- SHARE
-
- Close
- Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation
-
Yim J, Park SS, Lee JM, Yoon JH, Kim HJ, Min CK
- KMID: 2550206
- Blood Res.
- 2023 Dec;58(4):237-240.
- doi: 10.5045/br.2023.2023185
-
- CITED
-
- Close
- SHARE
-
- Close
- TP53 mutation is a high-risk factor for RichterÊs syndrome based on circulating tumor DNA
-
Park HS, Son BR, Son SM, Kwon J
- KMID: 2550202
- Blood Res.
- 2023 Dec;58(4):228-231.
- doi: 10.5045/br.2023.2023189
-
- CITED
-
- Close
- SHARE
-
- Close
- The association of pro-oxidant/antioxidant balance and blood parameters in patients with beta-thalassemia major: a cross-sectional study
-
Parvizi M, Moghaddam MD, Nazari S, Ashraf H, Aghdam MK
- KMID: 2550198
- Blood Res.
- 2023 Dec;58(4):201-207.
- doi: 10.5045/br.2023.2023174
Background Oxidative stress due to iron accumulation in patients with beta-thalassemia major (BTM) causes complications such as tissue damage and destruction. This study aimed to assess the association between the serum... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent advances in cellular immunotherapy for lymphoid malignancies
-
Chung H, Cho H
- KMID: 2550193
- Blood Res.
- 2023 Dec;58(4):166-172.
- doi: 10.5045/br.2023.2023177
Cellular immunotherapy with chimeric antigen receptor (CAR) T-cells has revolutionized the treatment of lymphoid malignancies. This review addresses the need for CAR expression in our endogenous T-cells to kill tumor... -
- CITED
-
- Close
- SHARE
-
- Close
- Correlation between red blood cell distribution width/platelet count and prognosis of newly diagnosed diffuse large B-cell lymphoma
-
Liu X, Bai Y, Liu Y, Li W, Cui Y, Xu J, Xiao X, Niu X, Sun K
- KMID: 2550196
- Blood Res.
- 2023 Dec;58(4):187-193.
- doi: 10.5045/br.2023.2023156
Background Red blood cell distribution width/platelet count ratio (RPR) is a reliable prognostic assessment indicator for numerous diseases. However, no studies to date have examined the relationship between RPR and the... -
- CITED
-
- Close
- SHARE
-
- Close
- Abdominal aortic calcification in patients newly diagnosed with essential thrombocythemia
-
Lee MW, Koh JS, Kang S, Ryu H, Song IC, Lee HJ, Yun HJ, Kim SY, Kim SS, Jo DY
- KMID: 2550194
- Blood Res.
- 2023 Dec;58(4):173-180.
- doi: 10.5045/br.2023.2023125
Background Although atherosclerosis is likely to be involved in the development of arterial thrombotic events in patients with essential thrombocythemia (ET), abdominal aortic calcification (AAC) has rarely been investigated. We evaluated... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment outcome and prognostic factors in relapsed pediatric acute myeloid leukemia
-
Lee JH, Ju HY, Hyun JK, Kim SJ, Cho HW, Lee JK, Lee JW, Sung KW, Yoo KH
- KMID: 2550195
- Blood Res.
- 2023 Dec;58(4):181-186.
- doi: 10.5045/br.2023.2023152
Background Despite improved outcomes for pediatric patients with acute myeloid leukemia (AML), the prognosis for relapse remains poor. This study aimed to examine the clinical factors associated with prognosis in relapsed... -
- CITED
-
- Close
- SHARE
-
- Close
- A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
-
Lee YP, Jung YJ, Cho J, Ko YH, Kim WS, Kim SJ, Yoon SE
- KMID: 2550199
- Blood Res.
- 2023 Dec;58(4):208-220.
- doi: 10.5045/br.2023.2023208
Background While treatment strategies for mantle cell lymphoma (MCL) have evolved, patients often experience disease progression and require additional treatment therapies. Ibrutinib presents a promising option for relapsed or refractory MCL... -
- CITED
-
- Close
- SHARE
-
- Close
- A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
-
Kim SJ, Do YR, Lee HS, Lee WS, Kong JH, Kwak JY, Eom HS, Moon JH, Yi JH, Lee JO, Jo JC, Yang DH
- KMID: 2550197
- Blood Res.
- 2023 Dec;58(4):194-200.
- doi: 10.5045/br.2023.2023206
Background Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL),... -
- CITED
-
- Close
- SHARE
-
- Close
